pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BlossomHill Therapeutics Inc · news · pharmadog
← back to BlossomHill Therapeutics Inc
News mentioning BlossomHill Therapeutics Inc
13
stories
Oct 15, 26
OrbiMed’s largest-ever Asian fund contributes to $3B war chest
fiercebiotech
Aug 10, 26
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
Aug 7, 26
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 7, 26
Updated: BlossomHill, Latigo cap four-IPO week with combined $496M haul
endpoints
Aug 6, 26
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Jul 24, 26
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 17, 26
Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugs
endpoints
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech